Stockscreener 앱 받기
16.68
2.77%
0.45
시간 외 거래:
16.68
전일 마감가:
$16.23
열려 있는:
$17.2
하루 거래량:
902.29K
Relative Volume:
0.47
시가총액:
$1.20B
수익:
-
순이익/손실:
$-230.32M
주가수익비율:
-4.7307
EPS:
-3.5259
순현금흐름:
$-196.04M
1주 성능:
-2.06%
1개월 성능:
-8.20%
6개월 성능:
-68.98%
1년 성능:
-58.22%
1일 변동 폭
$16.36
$17.20
1주일 범위
$16.22
$17.79
52주 변동 폭
$5.95
$62.75
문레이크 이뮤노테라퓨틱스 Stock (MLTX) Company Profile
명칭
Moonlake Immunotherapeutics
전화
41 41 510 8022
주소
DORFSTRASSE 29, ZUG
Compare MLTX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MLTX
Moonlake Immunotherapeutics
|
16.68 | 1.16B | 0 | -230.32M | -196.04M | -3.5259 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
문레이크 이뮤노테라퓨틱스 Stock (MLTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-15 | 다운그레이드 | Goldman | Neutral → Sell |
| 2026-01-09 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2025-11-03 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2025-10-02 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-10-01 | 다운그레이드 | Goldman | Buy → Neutral |
| 2025-09-30 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2025-09-30 | 다운그레이드 | Wolfe Research | Outperform → Underperform |
| 2025-09-29 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2025-09-29 | 다운그레이드 | Jefferies | Buy → Hold |
| 2025-09-29 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-09-29 | 다운그레이드 | Stifel | Buy → Hold |
| 2025-07-28 | 개시 | Rothschild & Co Redburn | Neutral |
| 2025-05-19 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2025-03-18 | 개시 | RBC Capital Mkts | Outperform |
| 2025-01-17 | 업그레이드 | Goldman | Neutral → Buy |
| 2024-11-05 | 재개 | Wedbush | Outperform |
| 2024-08-26 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2024-06-25 | 개시 | Oppenheimer | Outperform |
| 2024-04-02 | 개시 | Goldman | Neutral |
| 2024-02-15 | 개시 | Wolfe Research | Outperform |
| 2023-12-08 | 개시 | Citigroup | Buy |
| 2023-11-02 | 개시 | Stifel | Buy |
| 2023-09-14 | 다운그레이드 | Bryan Garnier | Buy → Neutral |
| 2023-08-31 | 개시 | Needham | Buy |
| 2023-06-15 | 개시 | Barclays | Equal Weight |
| 2023-05-01 | 개시 | Guggenheim | Buy |
| 2023-03-22 | 개시 | Wedbush | Outperform |
| 2023-03-09 | 개시 | BTIG Research | Buy |
| 2023-02-14 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-02-02 | 개시 | Bryan Garnier | Buy |
| 2022-11-11 | 개시 | Jefferies | Buy |
| 2022-08-25 | 개시 | SVB Leerink | Outperform |
| 2022-07-21 | 개시 | H.C. Wainwright | Buy |
| 2022-07-07 | 개시 | Cowen | Outperform |
모두보기
문레이크 이뮤노테라퓨틱스 주식(MLTX)의 최신 뉴스
MoonLake upgraded at Rothschild & Co Redburn (MLTX:NASDAQ) - Seeking Alpha
MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Gap Up After Analyst Upgrade - MarketBeat
MoonLake Immunotherapeutics (NASDAQ:MLTX) Upgraded by Rothschild & Co Redburn to Buy Rating - MarketBeat
MoonLake upgraded to Buy from Neutral at Rothschild & Co Redburn - TipRanks
Rothschild Redburn upgrades Moonlake stock on regulatory clarity - Investing.com
MoonLake stock soars as biotech fund reloads, takeover chatter ignites - MSN
MoonLake cut to sell at Goldman Sachs on risks to lead asset’s approval - MSN
MoonLake Immunotherapeutics (MLTX) price target increased by 11.25% to 22.30 - MSN
Caitong International Asset Management Co. Ltd Increases Holdings in MoonLake Immunotherapeutics $MLTX - MarketBeat
Earnings Beat: Will MoonLake Immunotherapeutics be affected by tariffs2026 EndofYear Setup & Entry Point Confirmation Signals - baoquankhu1.vn
RBC Capital Downgrades MoonLake Immunotherapeutics (MLTX) - MSN
This Fund Bought $28 Million of a Beaten-Down Immunotherapy Stock Last Quarter. What Should Long-Term Investors Know? - The Motley Fool
This fund acquired $28 million worth of a struggling immunotherapy stock last quarter. What important information should long-term investors consider? - Bitget
Boxer Capital Management LLC Acquires New Holdings in MoonLake Immunotherapeutics $MLTX - MarketBeat
Avoro Capital Advisors LLC Cuts Stock Position in MoonLake Immunotherapeutics $MLTX - MarketBeat
TD Cowen Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating - 富途牛牛
MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
MLTX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Analysts Conflicted on These Healthcare Names: MoonLake Immunotherapeutics (MLTX), Sarepta Therapeutics (SRPT) and vTv Therapeutics (VTVT) - The Globe and Mail
Clear Street Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Raises Target Price to $70 - 富途牛牛
Clear Street raises Moonlake stock price target on IL-17 data - Investing.com Nigeria
MoonLake price target raised to $70 from $45 at Clear Street - TipRanks
Clear Street raises Moonlake stock price target on IL-17 data By Investing.com - Investing.com Australia
How Investors Are Reacting To MoonLake Immunotherapeutics (MLTX) Widening Annual Net Loss Amid Share Price Gains - simplywall.st
Trading the Move, Not the Narrative: (MLTX) Edition - Stock Traders Daily
Rhenman & Partners Asset Management AB Buys 162,000 Shares of MoonLake Immunotherapeutics $MLTX - MarketBeat
MLTX Stock Gains 18% as Merck Reportedly Eyes Buyout - MSN
Is MoonLake Immunotherapeutics stock a smart buy before Fed meeting2026 EndofMonth & Verified Short-Term Trading Plans - Naître et grandir
TD Asset Management Inc Lowers Holdings in MoonLake Immunotherapeutics $MLTX - MarketBeat
Assessing MoonLake Immunotherapeutics (MLTX) Valuation After Positive Phase 2 Sonelokimab Results - simplywall.st
MoonLake Therapeutics Stock Sparks Retail Frenzy Ahead Of New York Summit — Traders See 'Nonstop Catalysts' Through 2026 - Stocktwits
HC Wainwright Issues Negative Outlook for MLTX Earnings - MarketBeat
What is HC Wainwright's Estimate for MLTX FY2027 Earnings? - MarketBeat
Wedbush Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $34 - 富途牛牛
MoonLake Immunotherapeutics (MLTX) Stock Analysis: Exploring a 34.94% Upside in the Biotech Sphere - DirectorsTalk Interviews
Cantor Fitzgerald reiterates Moonlake stock rating on axSpA potential - Investing.com
MoonLake Immunotherapeutics price target raised to $40 from $32 at H.C. Wainwright - TipRanks
MoonLake Immunotherapeutics (MLTX) Is Down 6.3% After Wider 2025 Loss And SLK BLA Timeline Update – Has The Bull Case Changed? - simplywall.st
Moonlake Immunotherapeutics stock price target raised to $40 by H.C. Wainwright on trial results - Investing.com India
MLTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Royal Bank Of Canada Boosts MoonLake Immunotherapeutics (NASDAQ:MLTX) Price Target to $13.00 - MarketBeat
Goldman Questions MoonLake Immunotherapeutics' (MLTX) Sonelokimab Approval Odds Despite Pipeline Update - Finviz
Goldman Questions MoonLake Immunotherapeutics’ (MLTX) Sonelokimab Approval Odds Despite Pipeline Update - Yahoo Finance
MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
RBC Raises Price Target on MoonLake Immunotherapeutics to $13 From $12, Keeps Sector Perform, Speculative Risk - marketscreener.com
Analysts Have Conflicting Sentiments on These Healthcare Companies: MoonLake Immunotherapeutics (MLTX) and Genfit (OtherGNFTF) - The Globe and Mail
MoonLake Immunotherapeutics price target raised to $35 from $30 at Oppenheimer - TipRanks
Stifel Downgrades MoonLake Immunotherapeutics(MLTX.US) to Hold Rating, Cuts Target Price to $19 - 富途牛牛
Assessing MoonLake Immunotherapeutics (MLTX) Valuation After Mixed Share Price Performance And Premium P/B Ratio - Yahoo Finance
MoonLake’s Sonelokimab Data Sharpens Risk Reward Profile Before Phase 3 - simplywall.st
MoonLake Immunotherapeutics (MLTX) Is Down 6.7% After Mixed 2025 Results And AxSpA Data UpdateWhat's Changed - Yahoo Finance
문레이크 이뮤노테라퓨틱스 (MLTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
문레이크 이뮤노테라퓨틱스 주식 (MLTX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Santos da Silva Jorge | Chief Executive Officer |
Dec 09 '25 |
Sale |
14.49 |
70,000 |
1,014,300 |
2,878,577 |
| Reich Kristian | Chief Scientific Officer |
Dec 08 '25 |
Sale |
15.08 |
130,000 |
1,960,400 |
72,908 |
| Reich Kristian | Chief Scientific Officer |
Dec 09 '25 |
Sale |
14.43 |
72,908 |
1,052,062 |
0 |
1.20%
0.06%
자본화:
|
볼륨(24시간):